CO25 Baseline Characteristics and Treatment Persistence in UK Patients With Moderate-to-Severe UC Following 12-Week Mirikizumab Induction: Real-World Data From IBD BioResource
Dec 1, 2025, 00:00
10.1016/j.jval.2025.09.127
https://www.valueinhealthjournal.com/article/S1098-3015(25)02684-1/fulltext
Title :
CO25 Baseline Characteristics and Treatment Persistence in UK Patients With Moderate-to-Severe UC Following 12-Week Mirikizumab Induction: Real-World Data From IBD BioResource
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)02684-1&doi=10.1016/j.jval.2025.09.127
First page :
Section Title :
Open access? :
No
Section Order :
11607